COMMUNIQUÉS West-GlobeNewswire

Ascendis Pharma Presents New Data and Updated Results from Phase 1/2 IL-Believe Trial at ASCO 2024
03/06/2024
- 40% of efficacy-evaluable patients (2 out of 5) in the initial cohort of patients with anti-PD-1 refractory melanoma treated with TransCon IL-2 β/γ in combination with TransCon TLR7/8 Agonist exhibited confirmed [...]
CloudMD Announces Filing and Mailing of the Management Information Circular in Connection with the Proposed Go-Private Transaction with CPS Capital
03/06/2024
Your vote is important no matter how many shares you hold. The Board of Directors of CloudMD unanimously recommends that Securityholders vote IN FAVOUR of the Arrangement Resolution. Questions or requests for voting [...]
BlueSphere Bio Announces IND Clearance of its First in Human Candidate and New Cell Therapy Portfolio for High-Risk Leukemia Patients
03/06/2024
TCX-101 Clinical Program : TCR T-Cell therapy product candidate (BSB-1001) to be delivered simultaneously with allogeneic stem cell transplant in patients with active disease or high risk of relapse First patient to be [...]
Oxford Treatment Center Launches The Rally Point: Valkyrie Program, a Specialty Program for Female Veterans
03/06/2024
OXFORD, Miss., June 03, 2024 (GLOBE NEWSWIRE) -- Oxford Treatment Center has launched a new specialized treatment program specifically tailored for female Veterans. The Rally Point: Valkyrie Program draws inspiration [...]
Public Hearings on Protecting and Improving Local Hospitals: Community members invited to give input
03/06/2024
TORONTO, June 03, 2024 (GLOBE NEWSWIRE) -- In response to more than 1,200 closures of emergency departments and other local hospital services over the last year, the Ontario Health Coalition (OHC) is holding public [...]
Late-breaking results from PALOMA-2 study of subcutaneous RYBREVANT®▼ (amivantamab) in combination with lazertinib show clinically meaningful antitumour response and improved safety profile in patients with EGFR-mutated non-small cell lung cancer
03/06/2024
Significantly lower infusion-related reactions seen with subcutaneous amivantamab compared with intravenous administration in new Phase 2 data 1 BEERSE, BELGIUM, June 03, 2024 (GLOBE NEWSWIRE) -- Janssen-Cilag [...]
Merus’ MCLA-129 Demonstrates Promising Single-Agent Efficiency in METex14 NSCLC in Poster Presentation at the 2024 ASCO® Annual Meeting
03/06/2024
UTRECHT, The Netherlands and CAMBRIDGE, Mass., June 03, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, full-length [...]
L’anticorps MCLA-129 produit par Merus ou la promesse d’une monothérapie efficace dans le traitement du CPNPC présentant une mutation de l’exon 14 du gène MET - une présentation sous forme de poster est prévue lors du congrès annuel 2024 de l’ASCO®
03/06/2024
UTRECHT, Pays-Bas et CAMBRIDGE, État du Massachusetts, 03 juin 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq : MRUS), ci-après « Merus, la Société, nous, ou notre », une société spécialisée dans l’oncologie au stade [...]
NADP Push for Greater Access to Dental Benefits Gaining Traction in Congress
03/06/2024
CBO estimates Independent Purchase of Dental Plans Would Reduce Deficit DALLAS, June 03, 2024 (GLOBE NEWSWIRE) -- After the National Association of Dental Plans (NADP) advocated for the passage of the Increasing Access [...]
Conor McGregor and Virat Kohli Collaborate to Launch TIDL's Innovative Pain Relief Products in India
03/06/2024
TIDL’s Game-Changing Products Now Rolling Out to 40,000 Stores Across India LOS ANGELES, June 03, 2024 (GLOBE NEWSWIRE) -- TIDL, the fastest-growing pain relief brand in the United States , is thrilled to announce its [...]
Inotiv Reaches Agreement to Resolve Previously-Announced Investigation into Shuttered Cumberland Facility
03/06/2024
Company reaffirms commitment to maintaining appropriate standards of animal welfare WEST LAFAYETTE, Ind., June 03, 2024 (GLOBE NEWSWIRE) -- Inotiv Inc. – Inotiv Inc. (“Inotiv” or the “Company”) (Nasdaq: NOTV), a leading [...]
7 Hills Pharma Receives $4.7MM Grant to Advance First-in-class Cell/Gene Therapy Technology into the Clinic
03/06/2024
HOUSTON, June 03, 2024 (GLOBE NEWSWIRE) -- 7 Hills Pharma Inc. (“7 Hills” or “7HP”), a clinical-stage pharma company leveraging a novel mechanism of action to safely enhance the effectiveness of cancer immunotherapies, [...]
Oswego Health Partners with Wellthy to Deliver Comprehensive Caregiving Support to Employees and their Families
03/06/2024
Oswego Health becomes the largest healthcare employer in Central New York to partner with Wellthy to support employee caregivers New York, NY, June 03, 2024 (GLOBE NEWSWIRE) -- Oswego Health – the Central New York [...]
Microbot Medical Announces $2.35 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules
03/06/2024
HINGHAM, Mass., June 03, 2024 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT) today announced that it has entered into definitive agreements for the purchase and sale of 1,566,669 shares of the Company’s common [...]
ALK launches new growth strategy and 2028 financial ambitions
03/06/2024
ALK ( ALKB:DC / OMX: ALK B / AKBLF ) today announced that the Board of Directors has adopted a new corporate strategy (Allergy + ) and 2028 financial ambitions. Allergy + aims to further strengthen ALK’s leadership in [...]
Crinetics Presents New Data at ENDO 2024 that Increases Body of Evidence Positioning Once-Daily, Oral Paltusotine as Potential First-Choice Treatment Option for Acromegaly
03/06/2024
First Scientific Presentation of PATHFNDR-2 Acromegaly Safety and Efficacy Data Following Positive Topline Announcement, Showing Rapid and Sustained IGF-1 Responses in People Treated with Paltusotine New PATHFNDR-1 [...]
HeartFlow AI Plaque Analysis Achieves Major Milestone Towards Medicare Coverage
03/06/2024
Coverage policy determination initiated with 5 Medicare MACs for HeartFlow's AI-QCT revolutionizing cardiovascular care for patients MOUNTAIN VIEW, Calif., June 03, 2024 (GLOBE NEWSWIRE) -- HeartFlow, a leader in [...]
Crinetics Announces Positive Initial Findings at ENDO 2024 for Atumelnant in Two Ongoing, Open-Label Studies for the Treatment of Congenital Adrenal Hyperplasia (CAH) and ACTH-Dependent Cushing’s Syndrome (ADCS)
03/06/2024
100% of Participants (n=6) With CAH Maintained Androstenedione (A4) Below the Upper Limit of Normal at all Time Points on Atumelnant (80 mg) CAH Participants Achieved More Than a 90% Reduction of A4 and 97% Reduction of [...]
CenTrak Announces Partnership with The Leapfrog Group
03/06/2024
Partner Advisory Committee Membership Demonstrates Enhanced Commitment to Healthcare Safety NEWTOWN, Pa., June 03, 2024 (GLOBE NEWSWIRE) -- CenTrak , the leader in real-time location technology solutions, announces its [...]

Pages